Modality
Radioligand
MOA
MDM2i
Target
IL-23
Pathway
Proteasome
Ovarian CaSchizophreniaHuntington's
Development Pipeline
Preclinical
~Sep 2018
→ ~Dec 2019
Phase 1
Mar 2020
→ Apr 2030
Phase 1Current
NCT05589701
2,940 pts·Ovarian Ca
2020-03→2030-04·Not yet recruiting
NCT03532346
2,367 pts·Ovarian Ca
2021-06→2028-06·Terminated
5,307 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-06-102.2y awayInterim· Ovarian Ca
2030-04-264.1y awayInterim· Ovarian Ca
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1
Not yet…
P1
Termina…
Catalysts
Interim
2028-06-10 · 2.2y away
Ovarian Ca
Interim
2030-04-26 · 4.1y away
Ovarian Ca
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05589701 | Phase 1 | Ovarian Ca | Not yet recr... | 2940 | PANSS |
| NCT03532346 | Phase 1 | Ovarian Ca | Terminated | 2367 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 |